Sands Capital Management
BMRN icon

Sands Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sands Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,565,620
Closed -$375M – 76
2019
Q3 		$375M Sell
5,565,620
-166,343
-3% -$12.8M 1.21% 27
2019
Q2 		$491M Sell
5,731,963
-149,483
-3% -$12.8M 1.46% 24
2019
Q1 		$522M Sell
5,881,446
-226,014
-4% -$20.9M 1.61% 23
2018
Q4 		$520M Sell
6,107,460
-339,085
-5% -$32.3M 1.86% 20
2018
Q3 		$625M Sell
6,446,545
-483,654
-7% -$48.3M 1.77% 20
2018
Q2 		$653M Sell
6,930,199
-317,652
-4% -$27.8M 1.87% 22
2018
Q1 		$588M Sell
7,247,851
-478,927
-6% -$41.1M 1.74% 23
2017
Q4 		$689M Sell
7,726,778
-331,781
-4% -$28.8M 2.09% 17
2017
Q3 		$750M Sell
8,058,559
-446,922
-5% -$39.5M 2.25% 17
2017
Q2 		$772M Sell
8,505,481
-466,924
-5% -$42.5M 2.32% 16
2017
Q1 		$788M Sell
8,972,405
-408,397
-4% -$36.3M 2.47% 14
2016
Q4 		$777M Sell
9,380,802
-840,480
-8% -$72.3M 2.71% 14
2016
Q3 		$946M Sell
10,221,282
-697,035
-6% -$65.6M 2.78% 14
2016
Q2 		$849M Sell
10,918,317
-643,187
-6% -$54.7M 2.63% 15
2016
Q1 		$954M Sell
11,561,504
-75,962
-0.7% -$6.18M 2.82% 13
2015
Q4 		$1.22B Buy
11,637,466
+241,600
+2% +$25.2M 3.14% 12
2015
Q3 		$1.2B Sell
11,395,866
-231,741
-2% -$31M 3.35% 11
2015
Q2 		$1.59B Sell
11,627,607
-707,845
-6% -$87.7M 3.91% 8
2015
Q1 		$1.54B Buy
12,335,452
+152,339
+1% +$16.1M 3.66% 11
2014
Q4 		$1.1B Buy
12,183,113
+84,485
+0.7% +$7.03M 2.62% 18
2014
Q3 		$873M Buy
12,098,628
+173,380
+1% +$11.4M 2.17% 23
2014
Q2 		$742M Buy
11,925,248
+2,187,583
+22% +$132M 1.87% 26
2014
Q1 		$664M Sell
9,737,665
-498,612
-5% -$36.7M 1.73% 27
2013
Q4 		$720M Sell
10,236,277
-32,535
-0.3% -$2.21M 1.88% 24
2013
Q3 		$741M Sell
10,268,812
-1,076,505
-9% -$71.5M 2.07% 22
2013
Q2 		$632M Buy
+11,345,317
New +$707M 2.13% 26

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management's BMRN Position: Q4 2019 in Review

Sands Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 5,565,620 shares — an estimated $375M sold.

Sands Capital Management first reported a position in BMRN in Q2 2013 and held it in 26 quarters. The position peaked at $1.59B in Q2 2015. 468 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

  • Sands Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Sands Capital Management sold 5,565,620 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $375M.
  • Sands Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 26 quarters.
  • Sands Capital Management's BioMarin Pharmaceuticals position peaked at $1.59B in Q2 2015.
  • 468 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Sands Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.